As cancer cells respond to cues in their microenvironment, they can enter a highly plastic state in which they are susceptible to transdifferentiation into a different type of cell. Researchers at the University of Basel ...
Jan 14, 2019
0
1615
Circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer, according ...
Dec 6, 2018
0
1
There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in ...
Oct 22, 2018
0
0
When treatment is working for a patient who is fighting cancer, the light at the end of the tunnel is easier to see.
Oct 17, 2018
0
14
A national survey of more than 1,000 women with metastatic breast cancer led by University of North Carolina Lineberger Comprehensive Cancer Center researchers found that nearly one-third of women had no insurance, and many ...
Oct 9, 2018
0
6
The research, led by Georgetown University Medical Center (GUMC) investigators and published in Neurotoxicity Research, complements findings from another GUMC-led study, published Oct. 3, that found a subset of breast cancer ...
Oct 4, 2018
0
8
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.
Sep 20, 2018
0
5
A team at the Salk Institute has identified a master switch that appears to control the dynamic behavior of tumor cells that makes some aggressive cancers so difficult to treat. The gene Sox10 directly controls the growth ...
Aug 31, 2018
0
262
Certain types of breast tumors can send signals that freeze the growth of their own secondary cancers, according to a major new study co-led by Australia's Garvan Institute of Medical Research.
Aug 27, 2018
0
426
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...
Aug 15, 2018
0
15
